Clinical Trials Browser

Phase 3 × olverembatinib × 90 days × Clear all

NCT06051409 2026-04-30

A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)

Phase 3 Recruiting

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma